{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T23:41:52Z","timestamp":1790379712891,"version":"4.1.0"},"reference-count":51,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2021,9,12]],"date-time":"2021-09-12T00:00:00Z","timestamp":1631404800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Tyrosine kinase inhibitors (TKIs) have shown long-term survival benefits in patients with chronic myeloid leukemia (CML). Nevertheless, significant concern has been raised regarding long-term TKI-associated vascular adverse events (VAEs). The objective of this retrospective cohort study was to investigate the incidence of VAEs in Taiwanese patients with CML treated with different TKIs (imatinib, nilotinib, and dasatinib) as well as potential risk factors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective cohort study using the Taiwan Cancer Registry Database and National Health Insurance Research Database. Adult patients diagnosed with CML from 2008 to 2016 were identified and categorized into three groups according to their first-line TKI treatment (imatinib, nilotinib, and dasatinib). Propensity score matching was performed to control for potential confounders. Cox regressions were used to estimate the hazard ratio (HR) of VAEs in different TKI groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In total, 1,111 patients with CML were included in our study. We found that the risk of VAEs in nilotinib users was significantly higher than that in imatinib users, with an HR of 3.13 (95% confidence interval (CI), 1.30\u20137.51), whereas dasatinib users also showed a nonsignificant trend for developing VAEs, with an HR of 1.71 (95% CI, 0.71\u20134.26). In multivariable logistic regression analysis, only nilotinib usage, older age, and history of cerebrovascular diseases were identified as significant risk factors. The annual incidence rate of VAEs was highest within the first year after the initiation of TKIs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>These findings can support clinicians in making treatment decisions and monitoring VAEs in patients with CML in Taiwan.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Implications for Practice<\/jats:title>\n                    <jats:p>This study found that patients with chronic myeloid leukemia (CML) treated with nilotinib and dasatinib may be exposed to a higher risk of developing vascular adverse events (VAEs) compared with those treated with imatinib. Thus, this study suggests that patients with CML who are older or have a history of cerebrovascular diseases should be under close monitoring of VAEs, particularly within the first year after the initiation of tyrosine kinase inhibitors.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/onco.13944","type":"journal-article","created":{"date-parts":[[2021,8,21]],"date-time":"2021-08-21T16:03:46Z","timestamp":1629561826000},"page":"974-982","source":"Crossref","is-referenced-by-count":16,"title":["Tyrosine Kinase Inhibitors and Vascular Adverse Events in Patients with Chronic Myeloid Leukemia: A\n                    <scp>Population-Based<\/scp>\n                    , Propensity\n                    <scp>Score-Matched<\/scp>\n                    Cohort Study"],"prefix":"10.1093","volume":"26","author":[{"given":"Mei-Tsen","family":"Chen","sequence":"first","affiliation":[{"name":"Graduate Institute of Clinical Pharmacy, National Taiwan University, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shih-Tsung","family":"Huang","sequence":"additional","affiliation":[{"name":"Graduate Institute of Clinical Pharmacy, National Taiwan University, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Wan","family":"Lin","sequence":"additional","affiliation":[{"name":"Graduate Institute of Clinical Pharmacy, National Taiwan University, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7965-7579","authenticated-orcid":false,"given":"Bor-Sheng","family":"Ko","sequence":"additional","affiliation":[{"name":"Division of Hematology, National Taiwan University Hospital, Taipei, Taiwan"},{"name":"Department of Hematological Oncology, National Taiwan University Cancer Center, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2098-5922","authenticated-orcid":false,"given":"Wen-Jone","family":"Chen","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3098-6371","authenticated-orcid":false,"given":"Huai-Hsuan","family":"Huang","sequence":"additional","affiliation":[{"name":"Division of Hematology, National Taiwan University Hospital, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1660-9120","authenticated-orcid":false,"given":"Fei-Yuan","family":"Hsiao","sequence":"additional","affiliation":[{"name":"Graduate Institute of Clinical Pharmacy, National Taiwan University, Taipei, Taiwan"},{"name":"School of Pharmacy, National Taiwan University, Taipei, Taiwan"},{"name":"Department of Pharmacy, National Taiwan University Hospital, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,9,12]]},"reference":[{"key":"2022011714460853700_onco13944-bib-0001","first-page":"748","volume-title":"Harrison's Principles of Internal Medicine","author":"Kantarjian","year":"2018","edition":"20th ed"},{"key":"2022011714460853700_onco13944-bib-0002","author":"Hughes"},{"key":"2022011714460853700_onco13944-bib-0003","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia","volume":"362","author":"Saglio","year":"2010","journal-title":"N Engl J Med"},{"key":"2022011714460853700_onco13944-bib-0004","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/S1470-2045(11)70201-7","article-title":"Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial","volume":"12","author":"Kantarjian","year":"2011","journal-title":"Lancet Oncol"},{"key":"2022011714460853700_onco13944-bib-0005","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1038\/leu.2012.134","article-title":"Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up","volume":"26","author":"Larson","year":"2012","journal-title":"Leukemia"},{"key":"2022011714460853700_onco13944-bib-0006","author":"Hughes"},{"key":"2022011714460853700_onco13944-bib-0007","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1038\/leu.2016.5","article-title":"Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial","volume":"30","author":"Hochhaus","year":"2016","journal-title":"Leukemia"},{"key":"2022011714460853700_onco13944-bib-0008","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1200\/JCO.2015.64.8899","article-title":"Final 5-year study results of DASISION: The dasatinib versus imatinib study in treatment-na\u00efve chronic myeloid leukemia patients trial","volume":"34","author":"Cortes","year":"2016","journal-title":"J Clin Oncol"},{"key":"2022011714460853700_onco13944-bib-0009","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"362","author":"Kantarjian","year":"2010","journal-title":"N Engl J Med"},{"key":"2022011714460853700_onco13944-bib-0010","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/S1470-2045(16)00080-2","article-title":"Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: An international, randomised, open-label, phase 3 trial","volume":"17","author":"Lipton","year":"2016","journal-title":"Lancet Oncol"},{"key":"2022011714460853700_onco13944-bib-0011","author":"Mauro"},{"key":"2022011714460853700_onco13944-bib-0012","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1002\/ajh.22037","article-title":"Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML","volume":"86","author":"Aichberger","year":"2011","journal-title":"Am J Hematol"},{"key":"2022011714460853700_onco13944-bib-0013","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.clml.2012.04.005","article-title":"Nilotinib-associated vascular events","volume":"12","author":"Quint\u00e1s-Cardama","year":"2012","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2022011714460853700_onco13944-bib-0014","author":"Rea"},{"key":"2022011714460853700_onco13944-bib-0015","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/ejh.12096","article-title":"Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in chronic myeloid leukemia: A single institution study","volume":"90","author":"Levato","year":"2013","journal-title":"Eur J Haematol"},{"key":"2022011714460853700_onco13944-bib-0016","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1093\/jnci\/djr292","article-title":"Severe peripheral arterial disease during nilotinib therapy","volume":"103","author":"Le Coutre","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"2022011714460853700_onco13944-bib-0017","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1182\/bloodadvances.2018028035","article-title":"The natural history of vascular and other complications in patients treated with nilotinib for chronic myeloid leukemia","volume":"3","author":"Minson","year":"2019","journal-title":"Blood Adv"},{"key":"2022011714460853700_onco13944-bib-0018","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1038\/leu.2013.70","article-title":"Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib","volume":"27","author":"Kim","year":"2013","journal-title":"Leukemia"},{"key":"2022011714460853700_onco13944-bib-0019","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1038\/leu.2013.69","article-title":"Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: A retrospective cohort analysis","volume":"27","author":"Giles","year":"2013","journal-title":"Leukemia"},{"key":"2022011714460853700_onco13944-bib-0020","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.3109\/10428194.2014.994205","article-title":"Real-life comparison of severe vascular events and other non-hematological complications in patients with chronic myeloid leukemia undergoing second-line nilotinib or dasatinib treatment","volume":"56","author":"Gora-Tybor","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"2022011714460853700_onco13944-bib-0021","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1182\/bloodadvances.2018025874","article-title":"Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs","volume":"3","author":"Jain","year":"2019","journal-title":"Blood Adv"},{"key":"2022011714460853700_onco13944-bib-0022","doi-asserted-by":"crossref","first-page":"161","DOI":"10.7326\/M15-2306","article-title":"Cardiovascular events associated with use of tyrosine kinase inhibitors in chronic myeloid leukemia: A population-based cohort study","volume":"165","author":"Dahl\u00e9n","year":"2016","journal-title":"Ann Intern Med"},{"key":"2022011714460853700_onco13944-bib-0023","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.3109\/10428194.2015.1091929","article-title":"Major arterial events in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: A meta-analysis","volume":"57","author":"Chai-Adisaksopha","year":"2016","journal-title":"Leuk Lymphoma"},{"key":"2022011714460853700_onco13944-bib-0024","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1182\/blood-2014-09-594432","article-title":"Vascular safety issues in CML patients treated with BCR\/ABL1 kinase inhibitors","volume":"125","author":"Valent","year":"2015","journal-title":"Blood"},{"key":"2022011714460853700_onco13944-bib-0025","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.clml.2018.12.004","article-title":"Cardiovascular risk and cardiovascular events in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors","volume":"19","author":"Assun\u00e7\u00e3o","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2022011714460853700_onco13944-bib-0026","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1001\/jamaoncol.2015.5932","article-title":"Association between BCR-ABL tyrosine kinase inhibitors for chronic myeloid leukemia and cardiovascular events, major molecular response, and overall survival: A systematic review and meta-analysis","volume":"2","author":"Douxfils","year":"2016","journal-title":"JAMA Oncol"},{"key":"2022011714460853700_onco13944-bib-0027","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1080\/14740338.2017.1261824","article-title":"Risk of arterial and venous occlusive events in chronic myeloid leukemia patients treated with new generation BCR-ABL tyrosine kinase inhibitors: A systematic review and meta-analysis","volume":"16","author":"Haguet","year":"2017","journal-title":"Expert Opin Drug Saf"},{"issue":"suppl 2","key":"2022011714460853700_onco13944-bib-0028","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/imj.13716","article-title":"Chronic myeloid leukaemia and tyrosine kinase inhibitor therapy: Assessment and management of cardiovascular risk factors","volume":"48","author":"Ross","year":"2018","journal-title":"Intern Med J"},{"key":"2022011714460853700_onco13944-bib-0029","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1038\/leu.2015.352","article-title":"Low incidence of peripheral arterial disease in patients receiving dasatinib in clinical trials","volume":"30","author":"Le Coutre","year":"2016","journal-title":"Leukemia"},{"key":"2022011714460853700_onco13944-bib-0030","author":"Taiwan Cancer Registry"},{"key":"2022011714460853700_onco13944-bib-0031","author":"National Health Insurance Administration"},{"key":"2022011714460853700_onco13944-bib-0032","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chron Dis"},{"key":"2022011714460853700_onco13944-bib-0033","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1093\/aje\/kwq433","article-title":"Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries","volume":"173","author":"Quan","year":"2011","journal-title":"Am J Epidemiol"},{"key":"2022011714460853700_onco13944-bib-0034","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1080\/00273171.2011.568786","article-title":"An introduction to propensity score methods for reducing the effects of confounding in observational studies","volume":"46","author":"Austin","year":"2011","journal-title":"Multivariate Behav Res."},{"key":"2022011714460853700_onco13944-bib-0035","author":"Jeon"},{"issue":"1","key":"2022011714460853700_onco13944-bib-0036","doi-asserted-by":"crossref","first-page":"e68","DOI":"10.1055\/s-0038-1624566","article-title":"BCR-ABL tyrosine kinase inhibitors: Which mechanism(s) may explain the risk of thrombosis?","volume":"2","author":"Haguet","year":"2018","journal-title":"TH Open"},{"key":"2022011714460853700_onco13944-bib-0037","doi-asserted-by":"crossref","first-page":"4210","DOI":"10.1200\/JCO.2015.62.4718","article-title":"Tyrosine kinase inhibitor-associated cardiovascular toxicity in chronic myeloid leukemia","volume":"33","author":"Moslehi","year":"2015","journal-title":"J Clin Oncol"},{"key":"2022011714460853700_onco13944-bib-0038","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.leukres.2017.05.008","article-title":"Risk factors and mechanisms contributing to TKI-induced vascular events in patients with CML","volume":"59","author":"Valent","year":"2017","journal-title":"Leuk Res"},{"key":"2022011714460853700_onco13944-bib-0039","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1016\/j.leukres.2007.01.024","article-title":"Impaired fasting glucose level as metabolic side effect of nilotinib in non-diabetic chronic myeloid leukemia patients resistant to imatinib","volume":"31","author":"Breccia","year":"2007","journal-title":"Leuk Res"},{"key":"2022011714460853700_onco13944-bib-0040","author":"Delphine"},{"key":"2022011714460853700_onco13944-bib-0041","doi-asserted-by":"crossref","first-page":"33944","DOI":"10.18632\/oncotarget.5580","article-title":"Effects of first-and second-generation tyrosine kinase inhibitor therapy on glucose and lipid metabolism in chronic myeloid leukemia patients: A real clinical problem?","volume":"6","author":"Iurlo","year":"2015","journal-title":"Oncotarget"},{"key":"2022011714460853700_onco13944-bib-0042","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1080\/03007995.2017.1399870","article-title":"Incidence of type 2 diabetes mellitus and hyperlipidemia in patients prescribed dasatinib or nilotinib as first-or second-line therapy for chronic myelogenous leukemia in the US","volume":"34","author":"Franklin","year":"2018","journal-title":"Curr Med Res Opin"},{"key":"2022011714460853700_onco13944-bib-0043","author":"Emir"},{"key":"2022011714460853700_onco13944-bib-0044","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1080\/10428194.2016.1239258","article-title":"Ponatinib reduces viability, migration, and functionality of human endothelial cells","volume":"58","author":"Gover-Proaktor","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"2022011714460853700_onco13944-bib-0045","author":"Hadzijusufovic"},{"key":"2022011714460853700_onco13944-bib-0046","doi-asserted-by":"crossref","first-page":"5198","DOI":"10.1182\/blood-2010-12-326850","article-title":"Dasatinib enhances megakaryocyte differentiation but inhibits platelet formation","volume":"117","author":"Mazharian","year":"2011","journal-title":"Blood"},{"key":"2022011714460853700_onco13944-bib-0047","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1002\/cam4.2687","article-title":"Varying effects of tyrosine kinase inhibitors on platelet function\u2014A need for individualized CML treatment to minimize the risk for hemostatic and thrombotic complications?","volume":"9","author":"Deb","year":"2020","journal-title":"Cancer Med"},{"key":"2022011714460853700_onco13944-bib-0048","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1002\/hon.2606","article-title":"Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart","volume":"37","author":"Caocci","year":"2019","journal-title":"Hematol Oncol"},{"key":"2022011714460853700_onco13944-bib-0049","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1007\/s00277-018-3412-8","article-title":"Features of vascular adverse events in Japanese patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: A retrospective study of the CML Cooperative Study Group database","volume":"97","author":"Fujioka","year":"2018","journal-title":"Ann Hematol"},{"key":"2022011714460853700_onco13944-bib-0050","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1177\/2040620718756603","article-title":"Safety and efficacy of nilotinib in routine clinical practice in patients with chronic myeloid leukemia in chronic or accelerated phase with resistance or intolerance to imatinib: Results from the NOVEL study","volume":"9","author":"Kuo","year":"2018","journal-title":"Ther Adv Hematol"},{"key":"2022011714460853700_onco13944-bib-0051","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1007\/s12185-019-02613-1","article-title":"Efficacy and safety of tyrosine kinase inhibitors for newly diagnosed chronic-phase chronic myeloid leukemia over a 5-year period: Results from the Japanese registry obtained by the New TARGET system","volume":"109","author":"Kizaki","year":"2019","journal-title":"Int J Hematol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/onco.13944","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/onco.13944","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/26\/11\/974\/42204042\/oncolo_26_11_974.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/26\/11\/974\/42204042\/oncolo_26_11_974.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,17]],"date-time":"2022-01-17T09:47:47Z","timestamp":1642412867000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/26\/11\/974\/6508790"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,12]]},"references-count":51,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2021,9,12]]},"published-print":{"date-parts":[[2021,11,1]]}},"URL":"https:\/\/doi.org\/10.1002\/onco.13944","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,11,1]]},"published":{"date-parts":[[2021,9,12]]}}}